Trajan offers a sanctuary for wellbeing at Pittcon 2016

Trajan offers a sanctuary for wellbeing at Pittcon 2016

March 07, 2016

Pittcon, Atlanta, Georgia, USA - 6 March 2016

Trajan Scientific and Medical (Trajan) is pleased to offer a sanctuary for wellbeing at Pittcon 2016, with professional massage therapists available at Booth 2556 to help delegates unwind from all the action of the conference.

Why? Trajan develops technologies to make a positive impact on human wellbeing.

In the spirit of wellness, Trajan’s booth this year draws attention to people, science and wellbeing.

However there is still room for technical details and development opportunities following last year’s unveiling of innovative technologies under the SGE brand.

Trajan continues to produce a range of analytical science consumables and components, while also extending their expertise and manufacturing capabilities to branch out into other fields of science and healthcare.

Chief Executive Officer of Trajan Stephen Tomisich said he was looking forward to reconnecting with longterm business partners, as well as forging new connections at Pittcon to discuss Trajan’s growing capabilities.

“From advanced photonics sensor technologies, expanding expertise in specialty glass forming and drawing, surface treatments and other areas, we are exploring new applications in analytical and medical devices.” said Mr Tomisich.

Trajan is increasing their presence in the Americas, relocating their current Austin, Texas office and warehouse this Spring, to a larger facility which will feature new production and kit assembly spaces.

The Trajan team is also growing with two recent additions in the US. Currently based out of Philadelphia, PA, is Mr Marc Neglia, Vice President of Sales for the Americas. Mr Neglia has an MBA from Drexel University, a Bachelor of Science (Electrical Engineering) from TESU, and over 20 years experience in relationship management, business development and sales in the scientific instrumentation market.

Mr Brian Jackson, has joined Trajan’s operations based in Austin, TX. He will focus on quality, process improvement, LEAN manufacturing and logistics. Complementary to his project management and production experience, Mr Jackson also has a Bachelor of Business Administration and Management from DeVry University.

On the opening of the exposition, Mr Tomisich said “Meet me and our team at Pittcon, to explore how we can work together to improve human wellbeing through science.”

Download
Trajan Press Release [PDF]

Media contact information
Trajan Scientific and Medical
media@trajanscimed.com
+61 (0) 3 9837 4200




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More